MOTS-c: AMPK, Mitochondria & Proposed Mechanisms

Metabolic-stress signaling

The mechanistic literature places MOTS-c in the conversation between the mitochondrion and the rest of the cell when metabolic stress is present. That sentence describes an experimental context, not a diagnosis and not a treatment.²

This page names the model for each finding: cell, mouse, or human measurement. If the model is missing, the finding cannot be read as a clinical result. The general map is in the MOTS-c hub.

A mechanism can be elegant and still be preclinical. The editorial temptation is to stack AMPK, folate, nucleus, and muscle until they sound like a therapy. Here they are stacked only as an inventory of hypotheses, each with its model in view.

AMPK

WADA classifies MOTS-c among AMPK activators on its 2026 list. That anti-doping status uses the same mechanistic family. It is not a proof of efficacy and is not discussed here as athlete guidance.⁵

That two systems — a laboratory paper and an anti-doping list — mention AMPK does not join their conclusions. One describes a model. The other classifies a substance. Neither publishes a clinical endpoint from human administration.

Folate and purine metabolism

The 2015 paper reported findings in folate and purine pathways. Those findings belong to the discovery work and to the systems in which they were measured. They are not a metabolic recipe for people.¹

Model: mainly experimental and preclinical. A biochemical pathway in a model does not establish that administering the peptide corrects a human metabolic disorder.

This page also does not turn folate and purine findings into a laboratory instruction for people. They are named because the 2015 paper measured them. Naming them does not authorize a clinical protocol.

Nuclear translocation

Kim and colleagues (2018) described MOTS-c translocating to the nucleus and regulating nuclear gene expression in response to metabolic stress. The paper’s title already places the finding in that cellular context.²

The paper also places part of that movement in an AMPK-dependent context. Again: the context is cellular. It is not copied onto a clinical endpoint.

NRF2 context

Part of the mechanistic literature links the nuclear program to antioxidant responses, including an NRF2 context where the finding supports it. NRF2 is a transcription factor tied to antioxidant-defense genes. Naming it does not demonstrate a clinical antioxidant benefit in people.²

Model: cellular. An antioxidant-response program in culture or in an experimental system is not a “mitochondrial health” outcome in a patient.

Skeletal-muscle research

The discovery work and later exercise and muscle work put skeletal muscle at the center of the experimental narrative. In mice, MOTS-c has been administered and muscle or physical-capacity outcomes have been measured. In people, endogenous MOTS-c has been measured in relation to exercise.^1,3

Those two sentences both use the word muscle. They do not use the same kind of evidence. The exercise page keeps that separation.³

If commercial copy says that MOTS-c “works in muscle like exercise,” it is mixing a mouse model, an endogenous measurement, and a metaphor. This page does not make that mix.

Identify the model

• Cell: nuclear translocation, gene-expression regulation, NRF2 context.²
• Mouse: peptide administration and metabolic or physical-capacity outcomes.^1,3
• Human measurement: endogenous MOTS-c in exercise or observation. Not peptide administration.³

NCT07505745 exists to test, in people, a hypothesis that began in the preclinical literature. Until results are posted, mechanism remains mechanism.⁴

What mechanism cannot conclude

A proposed mechanism does not establish human efficacy. AMPK, folate, purines, nuclear translocation, and NRF2 are pieces of a cellular and preclinical map. They do not become, by accumulation, a demonstrated metabolic therapy.^1,2

The metabolic hypothesis is discussed in metabolism and insulin. The definition is in What Is MOTS-c.